H.C. Wainwright Reiterates Sell, $0 PT on Sarepta (SRPT), 'see low likelihood of positive catalysts near-term'
Tweet Send to a Friend
H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Sell rating and $0 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
